PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Hammond, Edward ^a   Brandt, Ralf ^b   Dredge, Keith ^a,c  

^a Research and Development Progen Pharmaceuticals   (Australia)

^b vivoPharm   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARAN SULFATE; HEPARANASE; PG 545; PLACEBO; SORAFENIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; IN VIVO STUDY; LUNG; MASTECTOMY; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCURONIDASE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; SAPONINS;

MUS;

EID: 84871602830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052175     Document Type: Article

References (50)

1. Mina LA, Sledge GW, (2011) Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol 8: 325-332.
2. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
3. O'Shaughnessy J, (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3): 20-29.
4. Hayat MJ, Howlader N, Reichman ME, Edwards BK, (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12: 20-37.
5. Jones SE, (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8: 224-233.
6. Verma S, McLeod D, Batist G, Robidoux A, Martins IRS, et al. (2011) In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 16: 25-35.
7. Hammond E, Bytheway I, Ferro V (2006) Heparanase as a target for anticancer therapeutics: New developments and future prospects. In: Delehedde M, editor. New Developments in Therapeutic Glycomics. Trivandrum: Research Signpost. 251-282.
8. McKenzie E, (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151: 1-14.
9. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, et al. (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277: 3890-3903.
10. Dempsey LA, Brunn GJ, Platt PJ, (2000) Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 25: 349-351.
11. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15: 1661-1663.
12. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66: 1455-1463.
13. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, (2007) Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 361: 829-834.
14. Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, et al. (2002) Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 132: 326-333.
15. Imada T, Matsuoka J, Nobuhisa T, Okawa T, Murata T, et al. (2006) COX-2 induction by heparanase in the progression of breast cancer. Int J Mol Med 17: 221-228.
16. Götte M, Yip GW, (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66: 10233-10237.
17. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, et al. (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 118: 1609-1617.
18. Maxhimer JB, Pesce CE, Stewart RA, Gattuso P, Prinz RA, Xu X, (2005) Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. J Am Coll Surg 200: 328-335.
19. Theodoro TR, Luongo de Matos L, Sant Anna AVL, Fonseca FLA, Semedo P, et al. (2007) Heparanase Expression in Circulating Lymphocytes of Breast Cancer Patients Depends on the Presence of the Primary Tumor and/or Systemic Metastasis. Neoplasia 9: 504-510.
20. Raman K, Kuberan B, (2010) Chemical Tumor Biology of Heparan Sulfate Proteoglycans. Curr Chem Biol 4: 20-31.
21. Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D, (2011) MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 71: 645-654.
22. Liu C-J, Lee P-H, Lin D-Y, Wu C-C, Jeng L-B, et al. (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50: 958-968.
23. Borsig L, Vlodavsky I, Ishai-michaeli R, Torri G, Vismara E, (2011) Sulfated Hexasaccharides Attenuate Metastasis by Inhibition of P-selectin. Neoplasia 13: 445-452.
24. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, et al. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17: 1382-1393.
25. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, et al. (2011) M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PloS One 6: e21106.
26. De Bock K, Mazzone M, Carmeliet P, (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8: 393-404.
27. Dredge K, Hammond E, Davis K, Li CP, Liu L, et al. (2010) The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 28: 276-283.
28. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, et al. (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104: 635-642.
29. Sasaki M, Ito T, Kashima M, Fukui S, Izumiyama N, et al. (2001) Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro. Mediators Inflamm 10: 259-267.
30. Luan Q, Sun J, Li C, Zhang G, Lv Y, et al. (2011) Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression. Cancer Lett 308: 100-111.
31. Ebos JML, Kerbel RS, (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8: 210-221.
32. Holland SJ, Pan A, Franci C, Hu Y, Chang B, et al. (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70: 1544-1554.
33. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, et al. (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17: 163-170.
34. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS, (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
35. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
36. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, et al. (2011) Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17: 1101-1108.
37. Utsugi T, Shibata J, Sugimoto Y, (1996) Antitumor Activity of a Novel Podophyllotoxin Derivative (TOP-53) against Lung Cancer and Lung Metastatic Cancer Antitumor Activity of a Novel Podophyllotoxin Cancer and Lung Metastatic Cancer. Cancer Res 56: 2809-2814.
38. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
39. Sleeman J, Steeg PS, (2010) Cancer metastasis as a therapeutic target. Eur J Cancer 46: 1177-1180.
40. Sargent D, Hayes D, (2008) Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol 26: 1922-1933.
41. Hortobagyi G, Esserman L, Buchholz T (2010) Neoplasms of the breast. In: Holland-Frei, editor. Cancer Medicine. Shelten, Connecticut: PMPH. 1449.
42. Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, et al. (2009) Preclinical Drug Development Must Consider the Impact on Metastasis. Clin Cancer Res 15: 4529-4530.
43. Day C-P, Carter J, Bonomi C, Hollingshead M, Merlino G, (2012) Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin. Int J Cancer 130: 190-199.
44. Vlodavsky I, Abboud-Jarrous G, Elkin M, Naggi A, Casu B, et al. (2006) The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 35: 116-127.
45. Li Q-N, Liu H-Y, Xin X-L, Pan Q-M, Wang L, et al. (2009) Marine-derived oligosaccharide sulfate (JG3) suppresses heparanase-driven cell adhesion events in heparanase over-expressing CHO-K1 cells. Acta Pharmacol Sin 30: 1033-1038.
46. Gandhi N, Mancera R, (2010) Heparin/heparan sulphate-based drugs. Drug Discov Today 15: 1058-1069.
47. Le Dévédec SE, van Roosmalen W, Maria N, Grimbergen M, Pont C, et al. (2009) An improved model to study tumor cell autonomous metastasis programs using MTLn3 cells and the Rag2(-/-) gammac (-/-) mouse. Clin Exp Metastasis 26: 673-684.
48. Ebos JML, Lee CR, Kerbel RS, (2009) Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15: 5020-5025.
49. deMestre A, Khachigian L, Santiago F, Staykova M, Hulett M, (2003) Regulation of Inducible Heparanase Gene Transcription in Activated T Cells by Early Growth Response 1. J Biol Chem 278: 50677-50685.
50. de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, Hulett MD, (2005) Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 280: 35136-35147.